Key Takeaways MRK is set to report Q4 results on Feb. 3, with consensus calling for $16.19B in sales and$2.04 EPS.MRK's Q4 growth is expected from Keytruda, Animal Health and new drugs, partly offset by weaker MRK faces near-term pressure from Gardasil weakness, M&A-related costs & falling earnings estimates for 2026.Merck (MRK) is set to report its fourth-quarter and full-year 2025 earnings on Feb. 3, before market open. The Zacks Consensus Estimate for fourth-quarter sales and earnings is pegged at $16.1 ...